Printer Friendly

HOECHST-ROUSSEL, UPJOHN GUARANTEE ALTACE PRICE THROUGH END OF CENTURY

 HOECHST-ROUSSEL, UPJOHN GUARANTEE ALTACE PRICE THROUGH END OF CENTURY
 SOMERVILLE, N.J., April 30 /PRNewswire/ -- Hoechst-Roussel Pharmaceuticals Inc. and The Upjohn Company (NYSE: UPJ) announced today a guarantee that the manufacturer's price of Altace (ramipril) capsules will not be increased in the United States for the remainder of this century. Altace is a medication for 24-hour control of high blood pressure for most patients, usually with a once daily dosage.
 The Altace price guarantee, which is called The Altace Price Pledge 2000, is easy to administer and implement. The Price Pledge requires no patient enrollment, paperwork or administrative costs for patients, health-care providers, retailers, wholesalers or insurance companies.
 "The Altace Price Pledge 2000 is yet another way that we are seeking to be the preferred supplier to our customers -- patients, health-care providers, private institutions and governments," says Victor J. Bauer, Ph.D., president of Hoechst-Roussel Pharmaceuticals Inc. "The Price Pledge will help our customers keep the Altace part of their medical costs in control."
 The manufacturer's price of Altace is comparable to that of other new ACE inhibitors and less expensive than the older agents, explains Ley S. Smith, vice chairman of the board, The Upjohn Company. "The Altace Price Pledge 2000 goes further in meeting our customers' needs, by eliminating any time consuming or costly administration."
 Altace, which was introduced in the United States last year, is a potent, long-acting inhibitor of plasma and tissue ACE (angiotensin converting enzyme) that provides effective 24-hour blood pressure control with a convenient once-a-day dosage for most patients. It has a half life of 13 to 17 hours and a side-effect profile similar to other ACE inhibitors.
 Hoechst-Roussel Pharmaceuticals Inc. is part of the Life Sciences
Group of Hoechst Celanese Corporation. Hoechst Celanese, a wholly owned subsidiary of Hoechst AG of Germany, holds leading positions in chemicals, fibers, advanced materials and technologies and the life sciences.
 The Upjohn Company, based in Kalamazoo, Mich., is a worldwide, research-based provider of human health-care products, animal health products, agronomic and vegetable seeds and specialty chemicals. The company has been dedicated to improving health and nutrition for more than a century.
 -0- 4/30/92
 /CONTACT: Andrea Stine of Hoechst-Roussel Pharmaceuticals, 908-231-3752, or Jan R. AufderHeide of The Upjohn Company, 616-323-6546/
 (UPJ) CO: Hoechst-Roussel Pharmaceuticals Inc.; Upjohn Company ST: New Jersey, Michigan IN: MTC SU:


TS -- NY042 -- 4827 04/30/92 10:25 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 30, 1992
Words:397
Previous Article:ENRON REGISTRATION FOR EQUITY OFFERING BECOMES EFFECTIVE; STOCK PRICED AT $36.50 PER SHARE
Next Article:NEWMONT MINING IN JOINT VENTURE IN THAILAND; NEW GROUP WILL EXPLORE FOR GOLD


Related Articles
GLYNASE PRESTAB TABLETS RECEIVE THREE-YEAR MARKETING PROTECTION
HOECHST-ROUSSEL FORMS DERMATOLOGY DIVISION
LINCOMIX/SAFE-GUARD COMBINATION CLEARED FOR USE IN SWINE FEEDS
HOECHST-ROUSSEL PHARMACEUTICALS DONATES MEDICINE TO HELP FLORIDA RECOVERY
HOECHST-ROUSSEL PHARMACEUTICALS SETS NEW PRICING POLICY
HOECHST-ROUSSEL PHARMACEUTICALS SAYS ALTACE(R) (ramipril) CAPSULES TERMED 'APPROVABLE' BY FDA FOR POST-MI HEART FAILURE TREATMENT
HOECHST-ROUSSEL PHARMACEUTICALS GAINS CLEARANCE TO MARKET ALTACE(R) (RAMIPRIL) CAPSULES FOR POST-M.I. HEART FAILURE TREATMENT
King Pharmaceuticals and Hoechst Marion Roussel Sign an Agreement for One Of The Largest Single Product Transactions in Emerging Pharmaceutical...
King Pharmaceuticals Hires Former Altace(R) Product Manager.
King Pharmaceuticals and Medeva Pharmaceuticals Announce Copromotion Agreement.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters